You are here: Industry Insights > Fortacin

News List

Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis prnasia
July 29, 2021
Endurance RP Limited is pleased to announce that Fortacin™, a European, China ( Hong Kong, S.A.R., China and Macau, S.A.R., China ) approved treatment for PE receives a detailed market assessment by MME, one of the leading global market research companies
Fortacin™ Receives Strong Positive Results for US Phase II PRO Validation Study prnasia
July 16, 2021
Endurance RP Limited is pleased to announce the successful completion of prespecified data analysis from the United States study mandated patient reported outcome for PE.
Endurance RP Limited: A New Name, A New Perspective Eye on China's fertility and longevity market prnasia
June 24, 2021
Endurance RP Limited is pleased to announce the official completion of the rebranding of the Group, with the Company name changed to "Endurance RP Limited" with effect from 18 June 2021.
Regent Pacific's Unrealised Gain in Venturex Resources Limited Increased to US$10.74 million prnasia
May 12, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce several operational updates regarding its investment in Venturex Resources Limited and the approval and commercialisation ...
Regent Pacific Receives HK$24.96 million After Clinical Trial Approval For FORTACIN(TM) Has Been Obtained prnasia
April 02, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that the Group has received a payment of US$3.20 million (approximately HK$24.96 million) before deduction of PRC withholding ...
Regent Pacific Group Limited Announces the Successful Launch of Fortacin(TM) in Hong Kong, S.A.R., China, China, Upcoming Launches in Taiwan, China Region and China Macau, S.A.R., China, China and Related Business Updates prnasia
January 19, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that Fortacin™, the Group's prescription treatment for PE, went on sale in Hong Kong, S.A.R., China this January and will launch in
Regent Pacific Announces Key Progresses On FORTACIN(TM) / SENSTEND(TM) - Solution to Premature Ejaculation prnasia
January 05, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce several key updates of Fortacin™ / Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on ...
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application prnasia
December 03, 2020
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Pharmaceutical Marketing and Distribution Co., Ltd., a wholly controlled company of Shanghai Fosun Pharma ...